Market Overview

UPDATE: Stifel Nicolaus Initiates Edwards Lifesciences at Buy on Growth Outlook

Share:
Related EW
Jim Cramer Gives His Opinion On Synergy Pharmaceuticals And ABIOMED
Earnings Scheduled For April 26, 2016
Base-On-Base Patterns: Stocks Adopt Different Strokes In Choppy Markets (Investor's Business Daily)

Stifel Nicolaus initiated coverage on Edwards Lifesciences (NYSE: EW) with a Buy rating and a $113 price target.

Stifel Nicolaus noted, "We are initiating coverage of Edwards Lifesciences Corp. (EW) shares with a Buy rating and a $113 12-month target price. Over time, we think that Edwards' current market leading TAVR share (approximately 64% WW), its healthy new product pipeline, and the move into new geographies (e.g.Japan) will substantially expand the company's profitability and drive sustained above-industry-average growth through mid-decade. As the Transcatheter Valve Replacement market evolves further in years ahead, we believe Edwards is poised to benefit, driving significant top-line growth and operating leverage."

Edwards Lifesciences closed at $85.74 on Monday.

Latest Ratings for EW

DateFirmActionFromTo
Apr 2016CitigroupMaintainsSell
Apr 2016Cowen & CompanyMaintainsOutperform
Apr 2016JP MorganMaintainsOverweight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!